BACKGROUND: Extensive evidence implicates the Eph receptor family of tyrosine kinases and its ligand, ephrin, in glioma invasion, but it remains incompletely understood how these receptors affect chemotactic behavior of glioma. We sought to identify the Eph family members that correlate with patients' survival and to reveal the function of Eph in glioma invasion. METHODS: Clinical relevance of EphB genes was confirmed in a clinically annotated expression data set of 195 brain biopsy specimens. The function of EphB was analyzed in vitro and in vivo. RESULTS: Levels of mRNA of certain EphB members were significantly different in histological grades of glioma. According to Kaplan-Meier analysis, only the EphB1 level among 5 members of EphB emerged to be a powerful predictor of favorable survival in malignant glioma (n = 97, P = .0048), although the levels of EphB1 expression did not vary across the tumor grades. Immunoprecipitation showed that tyrosine phosphorylated EphB1 was not detected in all glioma cells tested. Forced overexpression and autophosphorylation of EphB1 in low expressor cell lines (U251, U87) did not affect cell migration or invasion in vitro, whereas EphB1 phosphorylation induced by ephrin-B2/Fc significantly decreased migration and invasion. Cells expressing ephrin-B2 showed noteworthy morphological changes consistent with migration induction; this alteration was negated by EphB1 overexpression. Concomitantly, overexpression of EphB1 abrogated the increased migration and invasion induced by ephrin-B2 in vitro and in vivo. CONCLUSIONS: These data suggest that ligand-dependent EphB1 signaling negatively regulates glioma cell invasion, identifying EphB1 as a favorable prognostic factor in malignant glioma.
BACKGROUND: Extensive evidence implicates the Eph receptor family of tyrosine kinases and its ligand, ephrin, in glioma invasion, but it remains incompletely understood how these receptors affect chemotactic behavior of glioma. We sought to identify the Eph family members that correlate with patients' survival and to reveal the function of Eph in glioma invasion. METHODS: Clinical relevance of EphB genes was confirmed in a clinically annotated expression data set of 195 brain biopsy specimens. The function of EphB was analyzed in vitro and in vivo. RESULTS: Levels of mRNA of certain EphB members were significantly different in histological grades of glioma. According to Kaplan-Meier analysis, only the EphB1 level among 5 members of EphB emerged to be a powerful predictor of favorable survival in malignant glioma (n = 97, P = .0048), although the levels of EphB1 expression did not vary across the tumor grades. Immunoprecipitation showed that tyrosine phosphorylated EphB1 was not detected in all glioma cells tested. Forced overexpression and autophosphorylation of EphB1 in low expressor cell lines (U251, U87) did not affect cell migration or invasion in vitro, whereas EphB1 phosphorylation induced by ephrin-B2/Fc significantly decreased migration and invasion. Cells expressing ephrin-B2 showed noteworthy morphological changes consistent with migration induction; this alteration was negated by EphB1 overexpression. Concomitantly, overexpression of EphB1 abrogated the increased migration and invasion induced by ephrin-B2 in vitro and in vivo. CONCLUSIONS: These data suggest that ligand-dependent EphB1 signaling negatively regulates glioma cell invasion, identifying EphB1 as a favorable prognostic factor in malignant glioma.
Authors: Eduard Batlle; Julinor Bacani; Harry Begthel; Suzanne Jonkheer; Suzanne Jonkeer; Alexander Gregorieff; Maaike van de Born; Núria Malats; Elena Sancho; Elles Boon; Tony Pawson; Steven Gallinger; Steven Pals; Hans Clevers Journal: Nature Date: 2005-06-23 Impact factor: 49.962
Authors: K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont Journal: Mol Cancer Res Date: 2015-05-05 Impact factor: 5.852
Authors: Shilpa Bhatia; Nimrah A Baig; Olga Timofeeva; Elena B Pasquale; Kellen Hirsch; Tobey J MacDonald; Anatoly Dritschilo; Yi Chien Lee; Mark Henkemeyer; Brian Rood; Mira Jung; Xiao-Jing Wang; Marcel Kool; Olga Rodriguez; Chris Albanese; Sana D Karam Journal: Oncotarget Date: 2015-04-20